Compared to the 20%–70% CHR rates and 30%–60% MR rates across several prospective clinical trials using various formulations of IFN‐α in MPN during the last two decades (Table 3), these responses were significantly better than those seen in most of the studies. The gene discussed is IFNA2; the disease is myeloproliferative disorder.